Indegene Limited has announced the launch of its new entity in Spain as part of its ongoing strategic expansion in Europe. The digital-first life sciences commercialization company aims to leverage this new establishment to drive innovation and transformation in the life sciences sector by accelerating AI-driven commercialization processes.
The Spain entity will act as a key delivery hub for Europe-based clients, with services spanning medical affairs, data and analytics, digital marketing, creative design, and customer experience. The move aligns with the company’s goal of enhancing hyper-personalization for healthcare providers and improving patient experiences.
Key highlights:
- Indegene aims to co-innovate with life sciences companies to help them modernize operations using data and AI.
- The expansion builds on Indegene’s significant presence in Europe, which includes centers in the UK, Germany, Ireland, and Switzerland.
- The Spain launch comes after notable acquisitions, such as Trilogy Writing & Consulting GmbH and DT Associates, to strengthen medical and regulatory capabilities.
Manish Gupta, Chairman and CEO of Indegene, emphasized Spain’s critical role as a talent and R&D hub for Europe, stating that this strategic step would enhance collaboration and innovation within the region.
With six operation hubs and 18 offices globally, Indegene continues to serve leading global biopharma and medical device companies, providing tailored solutions to meet diverse commercialization needs.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice.
